SYRE
Spyre Therapeutics·NASDAQ
--
--(--)
--
--(--)
2.75 / 10
Underperform
SYRE's fundamental score is 2.75/10, indicating significant challenges. Key weaknesses include low Net profit / Total profit ratio (0/3 score) and negative Asset-MV value (-0.5007), both placing it in less favorable performance groups. Profit-MV and Cash-MV show moderate positives but are outweighed by other deficits. Inventory and fixed assets turnover are strong, yet this is insufficient to offset broader quality issues. The stock is grouped as 'Underperform' with a fundamental quality score of 0/3, suggesting limited upside without material improvement in operational efficiency.
Analysis Checks(6/10)
Revenue-MV
Value-0.26
Score1/3
Weight10.92%
1M Return5.20%
Value-0.26
Score1/3
Weight10.92%
1M Return5.20%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.84%
1M Return-0.54%
Value36.70
Score1/3
Weight-0.84%
1M Return-0.54%
PB-ROE
Value0.95
Score0/3
Weight7.46%
1M Return3.56%
Value0.95
Score0/3
Weight7.46%
1M Return3.56%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.39%
1M Return0.86%
Value7979.42
Score3/3
Weight1.39%
1M Return0.86%
Cash-MV
Value-0.07
Score2/3
Weight16.37%
1M Return7.73%
Value-0.07
Score2/3
Weight16.37%
1M Return7.73%
Inventory turnover ratio
Value47.85
Score3/3
Weight9.60%
1M Return5.26%
Value47.85
Score3/3
Weight9.60%
1M Return5.26%
Profit-MV
Value0.46
Score2/3
Weight16.35%
1M Return7.79%
Value0.46
Score2/3
Weight16.35%
1M Return7.79%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.91%
1M Return1.15%
Value1.78
Score2/3
Weight1.91%
1M Return1.15%
Asset-MV
Value-0.50
Score2/3
Weight37.31%
1M Return15.13%
Value-0.50
Score2/3
Weight37.31%
1M Return15.13%
Net profit / Total profit (%)
Value99.98
Score0/3
Weight-0.48%
1M Return-0.30%
Value99.98
Score0/3
Weight-0.48%
1M Return-0.30%
Revenue-MV
Value-0.26
Score1/3
Weight10.92%
1M Return5.20%
Value-0.26
Score1/3
Weight10.92%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight9.60%
1M Return5.26%
Value47.85
Score3/3
Weight9.60%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.84%
1M Return-0.54%
Value36.70
Score1/3
Weight-0.84%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight16.35%
1M Return7.79%
Value0.46
Score2/3
Weight16.35%
1M Return7.79%
PB-ROE
Value0.95
Score0/3
Weight7.46%
1M Return3.56%
Value0.95
Score0/3
Weight7.46%
1M Return3.56%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.91%
1M Return1.15%
Value1.78
Score2/3
Weight1.91%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.39%
1M Return0.86%
Value7979.42
Score3/3
Weight1.39%
1M Return0.86%
Asset-MV
Value-0.50
Score2/3
Weight37.31%
1M Return15.13%
Value-0.50
Score2/3
Weight37.31%
1M Return15.13%
Cash-MV
Value-0.07
Score2/3
Weight16.37%
1M Return7.73%
Value-0.07
Score2/3
Weight16.37%
1M Return7.73%
Net profit / Total profit (%)
Value99.98
Score0/3
Weight-0.48%
1M Return-0.30%
Value99.98
Score0/3
Weight-0.48%
1M Return-0.30%
Is SYRE undervalued or overvalued?
- SYRE scores 2.75/10 on fundamentals and holds a Premium valuation at present. Backed by its -19.05% ROE, 0.00% net margin, -18.29 P/E ratio, 5.99 P/B ratio, and -35.33% earnings growth, these metrics solidify its Underperform investment rating.
